Watch for full data presentations at ESMO (Oct 23-27) — PFS and OS hazard ratios, safety profile, and subgroup analyses will determine regulatory filing strategy. Regulatory submissions to FDA/EMA for SAFFRON indication likely follow positive data. The SANOVO first-line data could support a China NDA expansion.
Price Chart
Executive Summary
HUTCHMED announced that two positive Phase III studies of savolitinib plus osimertinib in NSCLC were selected for oral presentations at the ESMO 2026 Congress, including a Presidential Symposium slot for the SAFFRON study. The SAFFRON study showed statistically significant improvement in PFS and OS versus chemotherapy, while the SANOVO study showed PFS improvement and clinically meaningful OS benefit versus osimertinib monotherapy. This is a significant clinical and regulatory milestone that could support label expansion for the combination globally.
Key Facts
- Two positive Phase III studies (SAFFRON global, SANOVO China) of savolitinib + osimertinib selected for oral presentations at ESMO 2026
- SAFFRON selected for Presidential Symposium (LBA6) — highest-profile session
- SAFFRON demonstrated statistically significant improvement in PFS and OS vs platinum-pemetrexed chemotherapy in EGFRm MET-overexpressed/amplified NSCLC post-osimertinib
- SANOVO (China) demonstrated statistically significant PFS improvement and clinically meaningful OS benefit vs osimertinib monotherapy in treatment-naïve EGFRm MET-overexpressed NSCLC
- ESMO Congress takes place October 23-27, 2026 in Madrid
- Savolitinib is jointly developed with AstraZeneca and commercialized as ORPATHYS
Financial Impact
Potential label expansion for savolitinib + osimertinib combination could significantly expand addressable patient population in NSCLC, a multi-billion dollar market. SAFFRON targets post-osimertinib MET-aberrant patients; SANOVO targets first-line MET-overexpressed patients.
Risk Factors
- Full data at ESMO may reveal safety concerns or less impressive subgroup results
- Regulatory approval not guaranteed despite positive Phase III results
- Competition from other MET-targeted therapies (e.g., amivantamab combinations)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3367914 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 26, 2026 today | Press Release | — | awaiting T+20 | — | — |
Oct 26, 2026 today | Press Release | — | awaiting T+20 | — | — |
Oct 21, 2026 5d ago | 6-K | $14.37 | awaiting T+20 | — | $14.27 (−0.70%) |
Sep 29, 2026 27d ago | 6-K | $14.15 | awaiting T+20 | — | $14.27 (+0.85%) |
Sep 28, 2026 27d ago | 6-K | $14.15 | awaiting T+20 | — | $14.27 (+0.85%) |
Sep 29, 2026 27d ago | Press Release | $14.63 | awaiting T+20 | — | $14.27 (−2.46%) |
Sep 24, 2026 4w ago | 6-K | $13.90 $14.28 | ▲ +2.73% | ▲ +3.15% | $14.27 (+2.66%) |
Sep 24, 2026 4w ago | Press Release | $13.94 $14.36 | ▲ +3.01% | ▲ +4.49% | $14.27 (+2.37%) |
Sep 3, 2026 7w ago | 6-K | $14.11 $14.20 | ▲ +0.64% | ▲ +1.83% | $14.27 (+1.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers